Tanzania						                            
                            
						
 Research Article
												Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures 						
Author(s): Nagi Kumar, Theresa Crocker, Tiffany Smith, Julio Pow-Sang, Philippe E. Spiess, Shanjayla Connors, Ganna Chornukur, Shohreh Iravani Dickinson, Wenlong Bai, Christopher R. Williams, Raoul Salup and Wui FuNagi Kumar, Theresa Crocker, Tiffany Smith, Julio Pow-Sang, Philippe E. Spiess, Shanjayla Connors, Ganna Chornukur, Shohreh Iravani Dickinson, Wenlong Bai, Christopher R. Williams, Raoul Salup and Wui Fu             
						
												
				 Inspite  of  the  large  number  of  promising  nutrient-derived  agents  demonstrating  promise  as  potential  chemopreventive agents, most have failed to prove effectiveness in clinical trials. Critical requirements for moving  nutrient-derived agents to recommendation for clinical use include adopting a systematic, molecular-mechanism  based  approach  and  utilizing  the  same  ethical  and  rigorous  methods  such  as  are  used  to  evaluate  other  pharmacological  agents.  Preliminary  data  on  a  mechanistic  rationale  for  chemoprevention  activity  as  observed  from  epidemiological,  in  vitro  and  preclinical  studies,  phase  I  data  of  safety  in  high-risk  cohorts  are  required  to  inform  design  of  phase  II  clinical  trials.  Additionally,  a  valid  panel  of  biomarkers  representing  the  hypothesized  carcinogenesis pathway for measuring efficacy mus.. Read More»
				  
												DOI:
												 10.4172/1948-5956.S3-007 
																	  
Cancer Science & Therapy received 5332 citations as per Google Scholar report